Libytec EPAVasc 3720mg 15 sachets

Despite significant advances in the prevention and treatment of cardiovascular disease, it remains a leading cause of death in most of the world.

Many clinical trials have shown that statin therapy can prevent cardiovascular events. According to recent guidelines, high-dose statin therapy is recommended for secondary prevention. However, despite achieving LDL-C values ​​≤ 70mg/dL, more than 20% of patients show disease progression. Therefore, reducing residual risk is an unmet medical goal.

The modern Western diet is rich in omega-6 and deficient in omega-3 fatty acids, resulting in a "pro-inflammatory" state in many individuals. EPA treatment, however, increases its levels in both plasma and tissues in a dose-dependent manner.

Administration of highly purified EPA has been shown to have pleiotropic beneficial effects on the development and progression of atherosclerotic plaque. EPA has been shown to reduce triglyceride and atherogenic lipoprotein levels.

EPA also has beneficial effects on endothelial function, oxidative stress, plaque formation/development and rupture, platelet aggregation, and thrombus formation.

According to the international literature, the administration of EPA (4g per day) to patients with borderline and slightly elevated triglyceride values ​​who were receiving statins, resulted in a fairly high and statistically significant 25% reduction in the risk of cardiovascular events (including cardiovascular death).

Vitamin D deficiency may predispose to hypertension, left ventricular hypertrophy, increased insulin resistance, atherosclerosis and adverse cardiovascular events. High levels of vitamin D are associated with a reduced risk of cardiovascular disease, type 2 diabetes and metabolic syndrome, while low levels are associated with an increased risk of myocardial infarction.

EPAVASC is a food supplement that offers the possibility of flexible administration of high doses of highly purified EPA. It is further enhanced for synergistic action with DHA and vitamin D which contribute to normal cardiovascular function.

The administration of the components of Epavasc is included in the international and Greek guidelines and is recommended by medical companies to high-risk cardiac patients (with high TG values).

The administration of EPAVASC can provide a positive effect:

• In the regulation of hypertriglyceridemia
• In the rate of progression of atherosclerotic plaque
• In reducing the risk of ischemic events
• In reducing residual coronary risk
• As additional treatment in secondary prevention in high-risk cardiac patients.